Philip Morris International U.S. White Paper: Misconceptions About Nicotine Among Medical Professionals, FDA Urged to Strengthen Public Education on “Smoke-Free Alternatives”

Key Points:

• Barrier to Tobacco Control: PMI’s new white paper reveals that misconceptions among healthcare providers about tobacco harm reduction science hinder smokers from receiving effective guidance.
•  
• Proposed Solution: The FDA should take a leadership role in educating healthcare providers about smoke-free alternatives and harm reduction.
• Supporting Data: About half of healthcare providers mistakenly believe nicotine is carcinogenic, and 93% say the FDA has a responsibility to share information about harm-reduction products.
• Practical Impact: Misinformation may cause smokers to miss safer alternatives, delaying progress in tobacco control.

According to PR Newswire (August 18), PMI America’s white paper draws on survey results from healthcare professionals across the United States, highlighting persistent confusion and longstanding misconceptions that prevent providers from offering smokers fully informed advice.

PMI America’s Chief Scientific and Regulatory Strategy Officer, Dr. Matthew Holman, stated:

“The FDA recognizes that smoke-free alternatives can play an important role in helping adult smokers quit cigarettes, improving both individual and public health. The next step is for the agency to share this information with frontline medical professionals—those most likely to be approached by smokers seeking help.”

The white paper was based on survey findings showing that many healthcare professionals are unfamiliar with the science supporting smoke-free products and tobacco harm reduction. This gap is particularly evident with nicotine. As the FDA itself acknowledges, nicotine is not the cause of the most serious health consequences of smoking—including fatal lung disease and cancer. The true culprits are the thousands of chemicals released in tobacco smoke.

This is why eliminating tobacco combustion is key to harm reduction. Yet nearly half of healthcare providers—and nearly 60% among those treating many smokers—wrongly believe nicotine is carcinogenic.

This information gap has real consequences. If smokers had access to the facts, they might switch to safer alternatives. While complete cessation of tobacco and nicotine remains the best choice, scientific evidence shows that adults who continue using nicotine can significantly reduce their exposure to harm by switching from traditional cigarettes to FDA-authorized smoke-free alternatives.

The white paper concludes:

“These are critical messages in the fight to end cigarette-related harm. The FDA must communicate them so that healthcare providers, as trusted advisors, can offer fact-based guidance to adult smokers and help them move away from combustible cigarettes.”

The report also noted that many providers are unaware of which nicotine products have been reviewed by regulators for safety and efficacy. Some do not even know that combustible cigarettes are the most harmful form of nicotine consumption. For adults aged 21 and over, FDA-authorized smoke-free products are a better choice compared to continued smoking.

Survey data further showed that 93% of healthcare professionals believe the FDA has a duty to share information if a specific smoke-free product is shown to lower risks of cancer, cardiovascular disease, or COPD compared to smoking, and 95% said they would pass that information on to their patients.

The white paper emphasized that adults of legal age who use nicotine need to be able to consult reliable sources, including their doctors and the FDA, to learn about safer alternatives to cigarettes when they do not plan to quit nicotine entirely.

It also called for the FDA to improve its review, authorization, and communication processes regarding safer alternatives available to adults 21 and over, while continuing to prevent youth access to nicotine products. Such measures, the paper argues, would be in the public health interest.

Currently, the U.S. lags behind many other countries in launching scientifically validated smoke-free products and encouraging adult smokers to adopt them. As former U.S. Secretary of Health and Human Services and current PMI America advisor Dr. Tom Price noted:

“Science should guide our policy. Unfortunately, when it comes to tobacco use—and particularly FDA-authorized smoke-free products—science has not been the driving force in policymaking.”